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Introduction: There are major controversies in screening for gestational diabetes mel-
litus (GDM). The present study evaluates the impact of the 2017 revised guidelines for 
GDM screening and a changed definition of GDM in Norway.
Material and methods: We used a case- series design and included women with no 
pre- pregnancy diabetes mellitus, who gave birth after gestational week 29 to a single-
ton fetus at the University Hospital of North Norway, Tromsø, or at a local maternity 
ward in Troms county, during the first 6 months of 2013 (before group, n = 676) and 
2018 (after group, n = 673). Data were collected from antenatal records, maternal 
health information sheets, and electronic medical records (Partus). We assessed the 
screening criteria age, parity, pre- pregnancy BMI, and ethnicity. Primary outcomes 
were change in size of the population eligible for GDM screening, screening adher-
ence, and prevalence of GDM, and follow up of GDM (treatment and obstetric risk 
assessment at gestational week 36). Statistical analyses were done using IBM SPSS 
with chi- squared test. A p value less than 0.05 was considered statistically significant.
Results: The proportion of women eligible for GDM screening increased from 46.4% 
in the before group to 67.6% in the after group (+45%) (p < 0.01). However, screening 
adherence among eligible women was only 28.3% and 49.2% in the before and after 
groups, respectively (p < 0.01). Among screened women, 16.9% (15/89) and 10.7% 
(24/224), respectively, were diagnosed with GDM, resulting in an overall estimated 
prevalence of 2.2% (15/676) and 3.6% (24/673). Among women diagnosed with GDM, 
13.3% received no follow up in 2013 and this proportion was 20.8% in 2018. The 
remaining women underwent obstetric risk assessment at gestational week 36 as ad-
vised in the guidelines.
Conclusions: The introduction of broader screening criteria and a more liberal case 
definition increased the population eligible for GDM screening by 45%. The higher 
proportion of women screened resulted in an insignificant higher prevalence of GDM. 
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1  |  INTRODUCTION
The definition of gestational diabetes mellitus (GDM), whether to 
offer systematic GDM screening or only test women at risk, and 
GDM screening criteria and treatment, have been subjects of great 
controversy since the introduction of the condition more than 
50 years ago.1 There is still insufficient evidence to suggest which 
thresholds for disease are best for diagnosing GDM.1– 6 This leads to 
uncertainties in choosing either a universal screening strategy or a 
more advanced strategy based on risk factors.2– 6 Different strate-
gies for screening and follow up have been investigated in studies 
of varying quality, which have shown small reduced risks of most 
negative maternal and perinatal outcomes compared with routine 
care among women with GDM.7 Despite these shortcomings, most 
countries have introduced GDM screening to improve the quality 
and outcomes of antenatal and obstetric care, as well as strategies 
for the prevention of metabolic diseases later in life.
The clinical guidelines of the Norwegian Society of Obstetrics 
and Gynecology recommended screening for GDM in 1998.8 These 
recommendations were complemented by national guidelines for 
screening, treatment, and follow up of GDM from the Norwegian 
Directorate of Health in 2005,9 with subsequent revisions in 2008,10 
2017,11 and 2020,12 in agreement with the diagnostic criteria and 
classification of GDM from the World Health Organization (WHO).13
In Norway, pregnant women are screened for GDM in primary 
health care during gestational weeks 24 through 28. In 2017, the 
guidelines changed from recommending the screening of all women 
aged 35 years or more regardless of parity, to recommending the 
screening of all nulliparous women aged 25 years or more and all 
multiparous woman aged 40 years or more. Furthermore, the pre-
vious recommendation to screen all women with a body mass index 
(BMI) from 27 kg/m2 was changed to include all women with a BMI 
of 25 kg/m2 or greater, whereas the ethnicity criterion changed 
from screening all women from “North Africa and the Indian sub-
continents” to women from “Asia and Africa”. Other changes were 
also made between 200810 and 201711 with regard to family history, 
glucose intolerance, and conditions in the previous and current preg-
nancy (Table 1). In 2008, the diagnostic criteria for GDM were fasting 
plasma glucose greater than 5.3 mmol/L and/or 2- hour oral glucose 
tolerance test (OGTT) of 9.0– 11.0 mmol/L, but this changed in the 
2017 revision to fasting plasma glucose greater than 7 mmol/L and/
or 2- hour OGTT of 7.8– 11.0 mmol/L. Opponents of the new guide-
lines have argued that expanding the screening criteria and changing 
the diagnostic criteria may lead to over- diagnosis and an increased 
burden on the healthcare system, and that evidence is lacking on 
the harms and significant benefits of such wide screening criteria.3– 5
In the present study, we evaluate the impact of changes in the 
screening and diagnostic criteria for GDM on the population eligible 
for GDM screening, screening adherence, the prevalence of GDM, 
and follow up of GDM (treatment and obstetric risk assessment at 
gestational week 36).
2  | MATERIAL AND METHODS
We used a retrospective case- series design to assess the impact of 
the 2017 revised guidelines for GDM by comparing women who 
gave birth in the first half of 2013 (before population) with women 
who gave birth in the first half of 2018 (after population) at the ma-
ternity clinic of the University Hospital of North Norway, Tromsø, 
and the local maternity wards at Finnsnes and Nordreisa. Data were 
collected from the antenatal fact sheet (Helsekort for gravide), mater-
nal health information sheets, and electronic medical records (Partus 
and hospital record).
A total of 1453 deliveries took place in the first 6 months of 
2013 (n = 740) and 2018 (n = 713). We excluded women with pre- 
pregnancy diabetes mellitus type 1 or 2 (n = 18; 13 in 2013 and 5 
in 2018), non- singleton pregnancies (n = 37; 18 in 2013 and 19 in 
2018), those who gave birth before gestational week 29 (n = 16; 6 
in 2013 and 10 in 2018), and those with incomplete data or missing 
medical records (n = 33; 27 in 2013 and 6 in 2018). The final ana-
lytical sample comprised 676 women in the before group and 673 
women in the after group.
Age and BMI were categorized according to the screening cri-
teria (17– 24, 25– 34, 35– 39, and 40– 47 years; 14.00– 24.99, 25.00– 
26.99, 27.00– 29.99, and 30.0– 56.99 kg/m2). Parity and ethnicity 
were dichotomized as nulliparous/parous and as high- risk (Asian/
African origin)/low- risk ethnicity (all others). We used a hierarchical 
approach when assigning women to risk groups, in which BMI had 
priority over age/parity, followed by ethnicity.
Screening adherence was poor in both study groups. Stakeholders for obstetric care 
need to consolidate quality measures and revisit the screening algorithm.
K E Y WO RD S
gestational diabetes mellitus, morbidity, pregnancy, prenatal care, prevalence, screening, 
screening adherence
Key message
Broadening screening criteria for gestational diabetes mel-
litus increased the number of women eligible for screening 
by 45%, with little impact on the prevalence of the disease.
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Primary end points were the size of the population eligible for 
GDM screening according to the considered screening criteria (age, 
parity, BMI, and ethnicity); screening adherence, defined as having a 
recorded fasting glucose test and/or a 2- hour OGTT result; and the 
prevalence of GDM in the study groups. Statistical analyses were 
performed using IBM SPSS version 26.0 with chi- squared test. A 
p value less than 0.05 was considered statistically significant.
2.1  |  Ethical approval
The Patient Ombudsman at the University Hospital of North 
Norway, Tromsø, authorized the study as a specific quality assurance 
study (reference 20197697; project no. 02223). As per current law, 
institutional review boards do not assess quality assurance studies 
in Norway.
3  |  RESULTS
There were no significant differences in the distribution of age, par-
ity, or ethnicity between the before and after groups (Table 2). The 
prevalence of women with a BMI of 25.00– 26.99 kg/m2 was far 
higher in the before group than the after group. Furthermore, there 
were significantly more women with a BMI above 30.0 kg/m2 in the 
before group, whereas there was no difference in the number of 
women with BMI of 27.0– 29.99 kg/m2 between the groups (Table 2). 
Overall, the before group had a significantly higher pre- pregnancy 
BMI than the after group (p < 0.01).
The population eligible for GDM screening increased from 46.6% 
in the before to 67.6% in the after group (p < 0.01; Table 3). Nearly 
12% of this increase was attributable to changes in the age/age and 
parity criteria, with the other 10% attributable to the BMI criterion. 
No change was observed for the ethnicity criterion.
Among women eligible for GDM screening, screening adherence 
was 28.3% (89/315) and 49.2% (224/455) in the before and after 
groups, respectively (Table 4; p < 0.01). Among screened women, 
62.9% of those in the before group were screened during the recom-
mended screening window, i.e. from gestational weeks 24 through 
28 (range 20– 36), compared with 71.4% (range 13– 37) of those in 
the after group. Most women screened outside the recommended 
screening window underwent screening at a later gestational week.
In the before and after groups, 16.9% (15/89) and 10.7% (24/224) 
of women, respectively, were diagnosed with GDM, resulting in 
an overall prevalence of 2.2% (15/676; 95% CI 1.1– 2.7) and 3.6% 
(24/673; 95% CI 2.2– 5.0) (p = 0.15).
In the before group, all women were diagnosed based on the 
 2- hour OGTT, including three women who also had an abnormal 
fasting glucose test, whereas 41.7% (10/24) of the GDM diagnoses 
in the after group were based a fasting glucose value alone (normal 
OGTT). The remaining cases were diagnosed based on the 2- hour 
OGTT and/or fasting glucose test.
In the before group, two (13.3%) women with GDM received no 
follow up, eight (53.3%) women were treated with lifestyle interven-
tions, and five (33.3%) were given insulin. No women were treated 
with metformin. In the after group, five (20.8%) women received 
no follow up, 13 (54.1%) were treated with lifestyle interventions, 
three (12.5%) with metformin, and three (12.5%) with insulin. All 





Age and parity ≥35 years regardless of parity ≥25 years and nulliparous
≥40 years and multiparous
Pre- pregnancy BMI BMI ≥27.0 kg/m2 BMI ≥25.0 kg/m2
Ethnicity From North Africa and the Indian subcontinent From Asia and Africa
Family history First- degree relative First- degree relative
Glucose intolerance Occasionally detected FPG between 6.1 and 7.0 mmol/L Impaired glucose tolerance
Previous pregnancy
Previous GDM Yes Yes
Previous macrosomia Yes Yes
Preeclampsia No Yes




Rapid fetal growth Yes No
Note: Marked area highlights screening criteria assessed in the study.
Abbreviation: BMI, body mass index; FPG, fasting plasma glucose.
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five women in the after group who did not receive follow up had 
fasting glucose values just above the threshold and normal OGTT 
values. One and two GDM cases gave birth before gestational week 
36 in the before and after groups, respectively, leaving 12 and 17 
women eligible for obstetric risk assessment at gestational week 
36. All these women had a specialist consultation, as advised in the 
guidelines.
The proportion of women having induction of labor increased 
significantly (chi- squared trend: p < 0.01) across status for GDM 
screening in both the before and after groups (Table 5, upper panel). 
Regarding mode of delivery there were no differences in outcomes 
between women having indication for screening, but not screened, 
compared with women screened, not having GDM (Table 5, lower 
panel). Women having indication for screening had significantly 
higher proportions of cesarean delivery, mainly emergency cesar-
ean deliveries, in both the before and after groups, compared with 
women having no indication for screening. However, the low prev-
alence of GDM in both the before and after groups made outcomes 
of mode of delivery in the GDM group insignificant in any compari-
son across status for screening (low sample size). Mean gestational 
age was significantly lower in the GDM group in the before group, 
and borderline significant in the after group, compared with women 
having no indication for screening (Table 6, upper panel). The overall 
prevalence of preterm birth was 5.6%, relatively consistent across 
status for screening and before/after groups. There was no differ-
ence in mean birthweight or Apgar score across status for screening 
and before/after groups (Table 6, middle panel or lower panel). The 
overall prevalence of shoulder dystocia was 1.01% (95% CI 0.42– 
1.60), none diagnosed among the GDM cases.
4  | DISCUSSION
By broadening the selection criteria and lowering the threshold for 
abnormality in the fasting glucose test and/or heightening the crite-
rion for pathological 2- hour OGTT, the proportion of women eligible 
for GDM screening increased by 45% (from 46.6% to 67.6%) after 
the introduction of the 2017 revised guidelines. Although adherence 
to screening increased from 28.6% to 49.2% in the before and after 
groups, this proportion is still low. Moreover, despite the increased 
proportion of women eligible for GDM screening and increased 
screening adherence, we observed only minor changes in the preva-
lence of GDM (2.2% to 3.6%; not significant).
When the 2017 revised national guidelines on GDM were intro-
duced in Norway, several authors claimed that expanding screening 
criteria could lead to massive over- screening and over- medicalization 
of healthy pregnant women.14 The Norwegian College of General 
Practice especially criticized the screening of all women aged 
25 years and above, pointing out that, because average age at first 
pregnancy is 29 years, the majority of pregnant women would ful-
fil at least one screening criterion, and estimating that over 70% of 
pregnant Norwegian women would be candidates for screening.15 
We found that 67.6% of women fulfilled at least one criterion for 
screening in 2018, and that the entire increase in screening eligibility 
from 2013 was attributable to changes in the age/parity and BMI cri-
teria. The proportion of women eligible for GDM screening has been 
reported to be similar in Portugal (68.2%), where risk factor- based 
screening is applied (BMI ≥30.0 kg/m2, history of GDM, macrosomic, 
i.e. ≥4000 g, newborns in previous pregnancies, or first- degree rela-
tives with type 2 diabetes mellitus).16
This study demonstrates that adherence to screening guidelines 
is unsatisfactorily low. A retrospective case- series of 2432 nullipa-
rous women in the United Kingdom and Ireland showed that 60.8% 
of women with identifiable risk factors for GDM were appropriately 
screened,17 whereas studies from Thailand and France reported 












17– 24 104 (15.4) 78 (11.6) 0.504
25– 34 415 (61.4) 445 (66.1)
35– 39 119 (17.6) 114 (16.9)
40– 47 38 (5.6) 36 (5.3)
Parity
Nulliparous 300 (44.4) 303 (45.0) 0.83
Parous 376 (55.6) 370 (55.0)
Pre- pregnancy BMI (kg/m²)
14.00– 24.99 338 (50.0) 419 (62.3) 0.000
25.00– 26.99 122 (18.0) 76 (11.3)
27.00– 29.99 92 (13.6) 87 (12.9)
30.00– 56.99 124 (18.3) 91 (13.5)
Ethnicity
Europe 622 (92.0) 604 (89.7) 0.255
Asia 23 (3.4) 36 (5.3)
Africa 29 (4.3) 28 (4.2)
Others 2 (0.3) 5 (0.7)
Abbreviation: BMI, body mass index.











Age and parity 0 23.5
Pre- pregnancy BMI 27.5 37.7
Ethnicity 4.6 4.0
Abbreviation: BMI, body mass index.
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screening rates of 78% and 80%, respectively.18,19 The latter stud-
ies were conducted in hospital and private clinic settings and had 
slightly different screening approaches.18,19 In a study from Sweden, 
where GDM screening is done similarly to Norway, 31% (257/822) of 
pregnant women had at least one risk factor for GDM, 31% (79/257) 
of whom were screened.20 Barriers to screening may include fail-
ure of healthcare workers to identify risk factors either at the first 
or subsequent antenatal visits. A less likely explanation may be that 
some pregnant women refuse screening and/or that midwives/gen-
eral practitioners neglect screening recommendations/borderline 
positive findings.21
A systematic review from 2017 on risk factor- based GDM 
screening reported that, when used as stand- alone criteria, BMI 
and high maternal age were as good as more complex prediction 
models.5 This is in line with a study from 2019 that demonstrated 
only a minor additive value (~1%) of expanding the age and BMI 
criteria to include factors like previous GDM, history of high birth-
weight, and first- degree family history of diabetes.22 This infor-
mation is reassuring for the validity of the present study, in which 
more general screening criteria were used and family history and 
risk factors associated with current and past pregnancies were not 
included (Table 1).
The prevalence of GDM in Norway increased from 3.0% in 2013 
to 5.0% in 2018; corresponding numbers for the two most northern 
counties, of which our study is part, were 2.3% and 2.8%, respec-
tively.23 Some authors claimed that the revised guidelines would 
double or triple the prevalence of GDM.24 In our study, nearly 50% 
of eligible women were screened in 2018. If we assume that all el-
igible women were screened, the prevalence would have doubled 






n n (%) n (%) 673
361 (53.4) No screening criterion 218 (32.4)
315 315 (46.6) Fulfilled at least one screening criterion 
(age, parity, pre- pregnancy BMI, 
ethnicity)
455 (67.6) 455
226 (71.7) Not screened 231 (50.8)
89 89 (28.3) Screened 224 (49.2) 224
74 (83.3) No GDM 200 (89.3)
15 15 (16.7) GDM 24 (10.7) 24
2 (13.3) Did not receive follow up 5 (20.8)
13 13 (86.7) Follow up 19 (79.2) 19
Abbreviations: BMI, body mass index; GDM, gestational diabetes mellitus.
TA B L E  4  Adherence to screening and 
follow up in the before and after group





Not screened Screened, no GDM Screened, GDM

















2013 n = 361% n = 225% n = 75% n = 15%
Normal vaginal delivery 81.4 71.6 70.7 80.0
Operative vaginal delivery 6.7 3.1 8.0 0.0
Planned cesarean delivery 3.3 8.0 8.0 0.0
Emergent cesarean delivery 8.6 17.3 13.3 20.0
2018 n = 218% n = 231% n = 200% n = 24%
Normal vaginal delivery 83.0 76.6 69.5 37.5
Operative vaginal delivery 4.6 6.5 8.0 20.8
Planned cesarean delivery 5.0 6.5 6.5 8.3
Emergent cesarean delivery 7.3 10.4 16.0 33.3
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non- significant increase in the prevalence of GDM between 2013 
(2.2%, 95% CI 1.1– 2.7) and 2018 (3.6%, 95% CI 2.2– 5.0) is attrib-
utable to both an increase the eligible population (46.6% to 67.6%) 
as a consequence of broader screening criteria, and an increase in 
screening adherence (28.67% to 49.2%).
In a Finnish study that employed a similar “before/after” design, 
screening was performed twice as often, and the prevalence of 
GDM increased from 7.2% to 11.3%, but this comprehensive screen-
ing effort did not improve pregnancy or neonatal outcomes.25 In the 
present study, there was a similar number of parturients in the first 
6 months of 2013 and 2018. The larger population eligible for GDM 
screening and higher screening adherence in 2018 led to the diagno-
sis of nine additional GDM cases. The detection rate among women 
eligible for GDM screening decreased from 16.9% (15/89) in 2013 
to 10.7% (24/224) in 2018, indicating less effective case identifica-
tion, with minimal, if any, impact on overall maternal and neonatal 
morbidity.
In 2013, all GDM diagnoses were based on the 2- hour OGTT (in-
cluding three cases with elevated fasting glucose values), whereas 
in 2018, 42% of cases were based solely on the fasting glucose 
test. Decisions on diagnostic thresholds are arbitrary and based 










2013 n = 361 n = 225 n = 75 n = 15
Mean 39.5* 39.4 39.8 38.2*
Standard error of 
mean
0.09 0.13 0.17 0.59
Range 33– 42 31– 42 36– 42 31– 40
2018 n = 218 n = 231 n = 200 n = 24
Mean 39.6** 39.3 39.4 38.7**
Standard error of 
mean
0.10 0.14 0.13 0.50
Range 33– 43 30– 43 30– 43 32– 42
Birthweight (g)
2013 n = 361 n = 225 n = 75 n = 15
Mean 3471 3491 3595 3539
Standard error of 
mean
27 37 60 182
Range 1571– 5030 1520– 4655 1901– 4600 1913– 4484
2018 n = 218 n = 231 n = 200 n = 24
Mean 3594 3486 3486 3516
Standard error of 
mean
35 35 39 157
Range 1944– 5130 1354– 4612 1206– 4875 1540– 5228
Apgar scrore at 5 minutes
2013 n = 361 n = 224a n = 75 n = 15
Mean 9.7 9.5 9.6 9.5
Standard error of 
mean
0.04 0.08 0.09 0.13
Range 4– 10 0– 10 6– 10 9– 10
2018 n = 218 n = 228b n = 200 n = 24
Mean 9.8 9.7 9.6 9.2
Standard error of 
mean
0.03 0.06 0.08 0.36
Range 8– 10 0– 10 0– 10 2– 10
aMissing information, one case.
bMissing information, three cases.
*p < 0.05; **p = 0.07.
TA B L E  6  Mean, standard error of 
mean, range gestational age, birthweight 
and 5- minute Apgar score by study group 
and screening status
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case ascertainment and treatment.26 Following the hyperglyce-
mia and adverse pregnancy outcomes (HAPO) study,27 the GDM 
threshold values recommended by the International Association 
of Diabetes and Pregnancy Study Groups (IADPSG) were not in 
accordance with any previous OGTT diagnostic values. The diag-
nostic criteria used in Norway are based on glucose values that 
reach an odds ratio of 2.0 for the adverse outcomes demonstrated 
in the HAPO study. The reliability of odds ratios derived from ob-
servational data is poor, and the fact that only one abnormal test 
(fasting plasma glucose or 2- hour OGTT) is required for a diagno-
sis further elucidates this problem.24 Fasting plasma glucose has 
low specificity, which limits its usefulness as a screening test.28 A 
systematic review of the 2- hour OGTT test concluded that “cau-
tion should be exercised when interpreting a single test result”.29 
Results from our study show that if GDM diagnosis was defined as 
positive results for both the fasting plasma glucose and the 2- hour 
OGTT, only three (3/676) women would have been diagnosed in 
2013, and seven (7/673) in 2018; hence the prevalence would have 
been minimal.
Seven cases (two in 2013 and five in 2018) received no follow 
up. In all these cases, pathological values were documented in the 
standard antenatal record, but the mother was not informed nor 
was she diagnosed with GDM. The “older” diagnostic criteria had 
a higher threshold for fasting glucose and a lower threshold for the 
2- hour OGTT, so healthcare providers may have failed to identify 
these women because of poor adaptation to the “old” and/or the 
“revised” diagnostic criteria.
Except for the seven women with no follow up, all diagnosed 
GDM cases were examined at week 36 in a maternity outpatient 
clinic, as advised in the guidelines. Few studies have analyzed adher-
ence to follow up in primary or specialist antenatal care following a 
GDM diagnosis. Most studies have focused on treatment, outcome, 
and postpartum follow up. A systematic review on the determinants 
of and barriers to GDM services found that there were serious bar-
riers to satisfying GDM services and management from screening to 
postpartum follow up, even in high- income countries.30
This study demonstrated that adherence to risk- based screen-
ing guidelines for GDM in Norway was poor both before and after 
implementation of the revised guidelines. The new guidelines led 
to a great increase in the number of women subjected to screen-
ing, followed by a small increase in the prevalence of GDM, which 
corresponds to the assumptions made by detractors of the revised 
guidelines. The new screening criteria have a major impact on costs 
and infrastructure capacity, and there is no clear evidence of the 
benefits of such a broad screening approach.21 Another consider-
ation is the impact of diagnosing asymptomatic pregnant women at 
a time when they might be particularly susceptible to stress, guilt, 
and anxiety.27
There is no evidence on whether the different screening alter-
natives improve outcomes that are important to patients.10 The 
revised guidelines led to a significant increase in the proportion 
of 2- hour OGTTs performed in primary health care. In total, the 
costs associated with broader GDM screening and consequent 
follow up/treatment are estimated at 16 million NOK.10 No cost– 
benefit analyses have been conducted to determine the cost 
savings related to preventing and treating the adverse outcomes 
related to short- and long- term complications; however, two stud-
ies have analyzed the cost- effectiveness of implementing broader 
screening criteria (based on IADPSG recommendations). One con-
cluded that it would be cost- effective only if detection of GDM 
reduced the rate of type 2 diabetes later in life.31 However, the 
long- term risk of developing type 2 diabetes among women with 
mild hyperglycemia identified with the broader screening criteria 
is unknown. The second study found that the revised screening 
algorithm would only be cost- effective if the number of cesarean 
sections were reduced.32 This is unlikely, as a diagnosis of GDM is 
associated with an increase in cesarean section rates, even if birth-
weight is normalized through treatment.33 A systematic review 
(2019) on the cost- effectiveness of controlling GDM concluded 
that neither screening nor treating mild GDM was convincingly 
cost- effective.33
The strengths of this study include its population- based ap-
proach, which reflects how screening is practiced, as well as 
the few parturients excluded because of missing information 
(n = 33/1349). Our study did not have the power to make any con-
clusion on clinical variables such as induction of labor, mode of 
delivery, and maternal/neonatal outcomes due to low numbers of 
GDM cases relative to non- cases, which is a limitation of the study. 
Another possible limitation is that not all risk factors for screening 
in the guidelines were included, but, as discussed by others, this 
fact has not had any effect on the true estimates of GDM.5,22
5  |  CONCLUSION
The broader screening criteria for GDM resulted in a large increase 
in the population eligible for screening. Screening adherence in-
creased, reaching nearly 50% in 2018, with only a minor impact on 
the prevalence of GDM. There may be concerns around the diagno-
sis of GDM, as 41% of screened women were diagnosed with GDM 
in 2018 based solely on fasting plasma glucose values. Stakeholders 
for obstetric care need to consolidate quality measures and revisit 
the screening algorithm.
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